Hulikal Narendra, Ray Satadru, Thomas Joseph, Fernandes Donald J
Department of Surgical Oncology, Sri Venkateswara Institute of Medical Sciences, SVIMS, Tirupati, Udupi, India E-mail :
Asian Pac J Cancer Prev. 2012;13(12):6087-91. doi: 10.7314/apjcp.2012.13.12.6087.
Patients diagnosed with a cancer have a life time risk of developing another de novo malignancy depending on various inherited, environmental and iatrogenic risk factors. Of late the detection of new primary has increased mainly due to refinement in both diagnostic and treatment modalities. Cancer victims are surviving longer and thus are more likely to develop a new metachronous malignancy.
To report our observed trend of increase in prevalence of both synchronous and metachronous second malignant neoplasms among cancer victims and to review the relevant literature.
A hospital based retrospective collection of prospective data of patients diagnosed with second denovo malignancy.
The study was conducted over a 5 year period from July 2008 to June 2012. All patients diagnosed with a histologically proven second malignancy as per Warren Gate's criteria were included. Various details regarding sex, age at presentation, synchronous or metachronous, treatment and outcome were recorded.
The occurrence of multiple primary malignancies is not rare. Awareness of the possibility alerts the clinician in evaluation of patients with a known malignancy presenting with unusual sites of metastasis. Individualizing the treatment according to the stages of the primaries will result in durable cancer control particularly in synchronous double malignancy.
根据各种遗传、环境和医源性风险因素，被诊断患有癌症的患者有患另一种新发恶性肿瘤的终生风险。近年来，新原发性肿瘤的检出率有所增加，主要是由于诊断和治疗方式的改进。癌症患者的存活时间更长，因此更有可能发生新的异时性恶性肿瘤。
报告我们观察到的癌症患者中同时性和异时性第二原发性恶性肿瘤患病率增加的趋势，并回顾相关文献。
基于医院对诊断为第二新发恶性肿瘤患者的前瞻性数据进行回顾性收集。
研究在2008年7月至2012年6月的5年期间进行。纳入所有根据沃伦·盖特标准经组织学证实为第二恶性肿瘤的患者。记录有关性别、就诊年龄、同时性或异时性、治疗和结果的各种细节。
多发性原发性恶性肿瘤的发生并不罕见。意识到这种可能性会提醒临床医生在评估已知恶性肿瘤且出现不寻常转移部位的患者时保持警惕。根据原发性肿瘤的阶段进行个体化治疗将实现持久的癌症控制，特别是在同时性双恶性肿瘤中。
